We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Invitrogen Gets Biotech Patent Win In Jury Trial

Law360 (July 26, 2006, 12:00 AM EDT) -- A long-running biotech patent infringement lawsuit between life science companies Invitrogen Corp. and Stratagene Corp. over a patent involving a process of creating competent E. coli cells was brought to a close by a Texas jury’s ruling on Tuesday.

The jury ruled that Invitrogen’s patent is valid and that Stratagene infringed on the patent, and awarded Invitrogen a 15% royalty rate on sales of Stratagene’s competent E. coli cell products between 1997 and 2004 for a total of $7.8 million.

Invitrogen was not entitled to lost...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.